Shares of GH Research climbed after the company said it would provide data from a trial of its drug for treatment-resistant depression. The stock rose 5.2%, to $11.15, in after-hours trading on Friday ...

GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders. GH Research PLC's initial focus is on developing its ...

A nasal spray that contains esketamine — a potent derivative of ketamine — can now be taken on its own to treat adults with ...

Little information has emerged about osavampator, a potentially first-in-class drug, since its promising Phase II performance last spring.

The one-two punch sent newly consolidated shares tumbling despite progress on its non-hallucinogenic depression treatment.

A bipartisan group of legislators have introduced a bill at the roundhouse that would allow New Mexicans to take psychedelic ...

Legislation to create a program for the medicinal use of psilocybin was introduced today in the New Mexico Senate. Senate Bill 219, the Medical Psilocybin Act, would allow those in New Mexico to ...

A group of lawmakers introduced a proposal Thursday to establish a program for medicinal use of psilocybin mushrooms.

The Cambridge, Mass., biotechnology company on Thursday said it received a notice of allowance from the U.S. Patent and Trademark Office regarding the drug candidate, ED-003, which is intended to ...

Ketamine therapy has become known for its effects at combating depression and other mood disorders. There’s a growing body of ...

Atai Life Sciences N.V. reported positive top-line phase 2a results of BPL-003 in treating Alcohol Use Disorder patients.

NeuroStar is committed to advancing the body of scientific research and elevating mental health treatment through robust research and data-driven innovation,” stated Keith J. Sullivan, President and ...